A Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome: Influence on Neurohormonal Activation and Clinical Outcomes

Comín‐Colet, Josep; Ruiz, Sonia; Cladellas, Mercè; Rizzo, M.; Torres, Alessandra; Bruguera, Jordi

doi:10.1016/j.cardfail.2009.05.010

Cited by 43 publications

(46 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…41,112 However, in these studies, the effect of the combination of ESAs and intravenous iron was examined, and not the effect of intravenous iron alone. The efficacy and safety of intravenous iron alone in patients with HF has been examined in five studies to date, but only three of these investigations were randomized, controlled studies (Table 1).…”

Section: Use Of Iron Supplementationmentioning

confidence: 99%

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Veldhuisen

Anker

Ponikowski³

et al. 2011

Nat Rev Cardiol

182

142

View full text Add to dashboard Cite

Anemia and iron deficiency are common in patients with heart failure (HF), and are associated with worse symptoms and adverse outcomes in this population. Although the two can occur together, anemia in HF is often not caused by iron deficiency, and iron deficiency can be present without causing anemia. Erythropoiesis-stimulating agents have been investigated extensively in the past few years and might be of benefit in patients with HF and anemia. However, concerns have arisen regarding the safety of erythropoiesis-stimulating agents in patients with chronic kidney disease and so the results of a large mortality trial are eagerly awaited to provide information on safety in patients with HF. Iron supplementation or replacement is a much older treatment option for patients with HF and anemia, but questions about the safety of intravenous iron, and absorption problems with oral formulations have prevented its widespread use to date. In the past few years, however, new data on the importance of iron deficiency in HF have become available, and a number of studies with intravenous iron have shown promising results. Therefore, this treatment approach is likely to become an attractive option for patients with HF and iron deficiency, both with and without anemia.

show abstract

Section: Use Of Iron Supplementationmentioning

confidence: 99%

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Veldhuisen

Anker

Ponikowski³

et al. 2011

Nat Rev Cardiol

182

142

View full text Add to dashboard Cite

show abstract

“…In a Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome study, combined therapy with intravenous (IV) iron and rHuEPO showed an increase Hb level, reduction of N-terminal pro-B-type natriuretic peptide (NT-proBNP), improvement of functional capacity and cardiovascular hospitalization in elderly patients with advanced CHF and cardio-renal anemia syndrome with mild to moderate renal dysfunction [29]. …”

Section: Epo and Cardiovascular Protectionmentioning

confidence: 99%

Erythropoietin update 2011

et al. 2011

View full text Add to dashboard Cite

SummaryTraditionally, erythropoietin (EPO) is described as a hematopoietic cytokine, regulating proliferation and differentiation and survival of the erythroid progenitors. The recent finding of new sites of EPO production and the wide spread distribution of EPO receptors (EPO-R) on endothelial cells, cardiomyocytes, renal cells as well as the central and peripheral nervous system raised the possibility that EPO may exert pleiotropic actions on several targets. Indeed studies (mainly preclinical) have documented protective, non-hematopoietic, abilities of EPO in a variety of tissue. However, the data obtained from clinical studies are more skeptical about these properties. This article provides a comprehensive overview of EPO and its derivatives.

show abstract

“…Design n Clinical context Outcomes Bolger et al 33 Open, non-controlled; IV iron sucrose 16 Hb ≤12 g/dl; NYHA II/III ↑Hb (1.4 g/dl); ↑QoL (MLHF); ↑6-min WT (44 m) Usmanov et al 34 Open, non-controlled; IV iron 32 Hb <11 g/dl; NYHA III/IV ↑Hb (3---3.3 g/dl); ↓ LV remodeling Comin-Colet et al 35 Open; IV iron sucrose+EPO vs. no treatment…”

Section: Studymentioning

confidence: 99%

“…Six studies have been published on iron supplementation in HF, including two open non-controlled trials, 33,34 one open controlled trial, 35 and three randomized placebocontrolled, double-blind trials 36---38 (Table 2). Improvements in symptoms, exercise capacity and quality of life were seen in parallel with rises in Hb levels in all these studies.…”

Section: Intravenous Iron Supplementationmentioning

confidence: 99%

Anemia e deficiência de ferro na insuficiência cardíaca

Gil

Ferreira

2014

Revista Portuguesa de Cardiologia

View full text Add to dashboard Cite

Heart failure is a common problem and a major cause of mortality, morbidity and impaired quality of life. Anemia is a frequent comorbidity in heart failure and further worsens prognosis and disability. Regardless of anemia status, iron deficiency is a common and usually unidentified problem in patients with heart failure. This article reviews the mechanisms, impact on outcomes and treatment of anemia and iron deficiency in patients with heart failure. © 2013 Sociedade Portuguesa de Cardiologia Published by Elsevier España, S.L. All rights reserved. PALAVRAS-CHAVEAnemia; Deficiência de ferro; Insuficiência cardíaca; Terapêutica com ferro Anemia e deficiência de ferro na insuficiência cardíacaResumo A insuficiência cardíaca é uma patologia comum e uma causa importante de mortalidade, morbilidade e deterioração da qualidade de vida. A anemia é uma comorbilidade frequente na insuficiência cardíaca e agrava o seu prognóstico e capacidade funcional. Independentemente da presença ou não de anemia, a deficiência de ferro é um problema associado à insuficiência cardíaca muitas vezes não identificado. Este artigo revê os mecanismos, impacto prognóstico e tratamento da anemia e deficiência de ferro. © 2013 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L. Todos os direitos reservados. Case studyA 72-year-old woman with a history of poorly controlled hypertension under diuretic therapy for the previous 10 years was assessed for fatigue and dyspnea on minimal ଝ Please cite this article as: Gil VM, Ferreira JS. Anemia e deficiência de ferro na insuficiência cardíaca. Rev Port Cardiol. 2014;33:39---44.* Corresponding author. E-mail address: victorgilmd@gmail.com (V.M. Gil).exertion (NYHA class III). Her blood pressure was 150/85 mmHg and her heart rate was 88 bpm; she had faint crackles in the lung bases and ankle edema. The ECG showed voltage criteria for left ventricular hypertrophy. Her hemoglobin (Hb) level was 11.0 g/dl and her mean corpuscular volume was 85 fl, blood glucose 102 mg/dl, total cholesterol 190 mg/dl and creatinine 1 mg/dl. She was medicated with furosemide, a renin-angiotensin system inhibitor and a beta-blocker, and was referred for echocardiographic assessment. What role did the patient's Hb of 11 g/dl play in her clinical setting?

show abstract

A Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome: Influence on Neurohormonal Activation and Clinical Outcomes

Cited by 43 publications

References 30 publications

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches

Erythropoietin update 2011

Anemia e deficiência de ferro na insuficiência cardíaca

Contact Info

Product

Resources

About